Dialysis Clinic, Inc is a medicare approved dialysis facility center in Bellevue, Nebraska and it has 12 dialysis stations. It is located in Sarpy county at 4112 Twin Creek Dr, Bellevue, NE, 68123. You can reach out to the office of Dialysis Clinic, Inc at (402) 934-9560. This dialysis clinic is managed and/or owned by Dialysis Clinic, Inc.. Dialysis Clinic, Inc has the following ownership type - Non-Profit. It was first certified by medicare in July, 2004. The medicare id for this facility is 282524 and it accepts patients under medicare ESRD program.
Name | Dialysis Clinic, Inc |
---|---|
Location | 4112 Twin Creek Dr, Bellevue, Nebraska |
No. of Dialysis Stations | 12 |
Medicare ID | 282524 |
Managed By | Dialysis Clinic, Inc. |
Ownership Type | Non-Profit |
Late Shifts | No |
4112 Twin Creek Dr, Bellevue, Nebraska, 68123 | |
(402) 934-9560 | |
News Archive
The first phase of a landmark study of complications of tuberculosis - the first ever carried out in Africa - has been completed by researchers at Wythenshawe Hospital and the University of Manchester working with colleagues in Uganda.
Several organization led by the WHO have contributed $5 billion for a campaign aimed at distributing 700 million bednets to prevent malaria in sub-Saharan Africa by 2015, the East African reports.
Vismodegib (trade name: Erivedge) has already been approved since 2013 for the treatment of patients with locally advanced basal cell carcinoma (BCC) or symptomatic metastatic BCC and has already undergone an early benefit assessment according to the Act on the Reform of the Market for Medicinal Products.
In a small study that included 25 patients with hereditary hemorrhagic telangiectasia (a genetic disorder that leads to abnormalities of blood vessels) and severe liver involvement with this disease, patients who received the drug bevacizumab had improved cardiac output and a reduction in the duration and number of episodes of nose bleeds, a potentially life-threatening complication for patients with this disorder, according to a study in the March 7 issue of JAMA.
› Verified 3 days ago
NPI Number | 1861425340 |
Doing Business As | Dialysis Clinic Inc. |
Address | 4112 Twin Creek Dr Bellevue, Nebraska, 68123 |
Phone Number | (402) 342-0190 |
News Archive
The first phase of a landmark study of complications of tuberculosis - the first ever carried out in Africa - has been completed by researchers at Wythenshawe Hospital and the University of Manchester working with colleagues in Uganda.
Several organization led by the WHO have contributed $5 billion for a campaign aimed at distributing 700 million bednets to prevent malaria in sub-Saharan Africa by 2015, the East African reports.
Vismodegib (trade name: Erivedge) has already been approved since 2013 for the treatment of patients with locally advanced basal cell carcinoma (BCC) or symptomatic metastatic BCC and has already undergone an early benefit assessment according to the Act on the Reform of the Market for Medicinal Products.
In a small study that included 25 patients with hereditary hemorrhagic telangiectasia (a genetic disorder that leads to abnormalities of blood vessels) and severe liver involvement with this disease, patients who received the drug bevacizumab had improved cardiac output and a reduction in the duration and number of episodes of nose bleeds, a potentially life-threatening complication for patients with this disorder, according to a study in the March 7 issue of JAMA.
› Verified 3 days ago
Dialysis patients with Hemoglobin data | 30 |
Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 7 |
News Archive
The first phase of a landmark study of complications of tuberculosis - the first ever carried out in Africa - has been completed by researchers at Wythenshawe Hospital and the University of Manchester working with colleagues in Uganda.
Several organization led by the WHO have contributed $5 billion for a campaign aimed at distributing 700 million bednets to prevent malaria in sub-Saharan Africa by 2015, the East African reports.
Vismodegib (trade name: Erivedge) has already been approved since 2013 for the treatment of patients with locally advanced basal cell carcinoma (BCC) or symptomatic metastatic BCC and has already undergone an early benefit assessment according to the Act on the Reform of the Market for Medicinal Products.
In a small study that included 25 patients with hereditary hemorrhagic telangiectasia (a genetic disorder that leads to abnormalities of blood vessels) and severe liver involvement with this disease, patients who received the drug bevacizumab had improved cardiac output and a reduction in the duration and number of episodes of nose bleeds, a potentially life-threatening complication for patients with this disorder, according to a study in the March 7 issue of JAMA.
› Verified 3 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
Adult patients getting regular hemodialysis at the center | 59 |
Adult patient months included in Kt/V greater than or equal to 1.2 | 497 |
Percentage of adult patients getting regular hemodialysis at the center | 95 |
Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
The first phase of a landmark study of complications of tuberculosis - the first ever carried out in Africa - has been completed by researchers at Wythenshawe Hospital and the University of Manchester working with colleagues in Uganda.
Several organization led by the WHO have contributed $5 billion for a campaign aimed at distributing 700 million bednets to prevent malaria in sub-Saharan Africa by 2015, the East African reports.
Vismodegib (trade name: Erivedge) has already been approved since 2013 for the treatment of patients with locally advanced basal cell carcinoma (BCC) or symptomatic metastatic BCC and has already undergone an early benefit assessment according to the Act on the Reform of the Market for Medicinal Products.
In a small study that included 25 patients with hereditary hemorrhagic telangiectasia (a genetic disorder that leads to abnormalities of blood vessels) and severe liver involvement with this disease, patients who received the drug bevacizumab had improved cardiac output and a reduction in the duration and number of episodes of nose bleeds, a potentially life-threatening complication for patients with this disorder, according to a study in the March 7 issue of JAMA.
› Verified 3 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Dialysis Clinic, Inc with elevated calcium levels.
Patients with hypercalcemia | 60 |
Hypercalcemia patient months | 509 |
Patients with Serumphosphor | 64 |
Patients with Serumphosphor less than 3.5 mg/dL | 7 |
Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 29 |
Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 36 |
Patients with Serumphosphor from 5.6 to 7 mg/dL | 17 |
Patients with Serumphosphor greater than 7 mg/dL | 12 |
News Archive
The first phase of a landmark study of complications of tuberculosis - the first ever carried out in Africa - has been completed by researchers at Wythenshawe Hospital and the University of Manchester working with colleagues in Uganda.
Several organization led by the WHO have contributed $5 billion for a campaign aimed at distributing 700 million bednets to prevent malaria in sub-Saharan Africa by 2015, the East African reports.
Vismodegib (trade name: Erivedge) has already been approved since 2013 for the treatment of patients with locally advanced basal cell carcinoma (BCC) or symptomatic metastatic BCC and has already undergone an early benefit assessment according to the Act on the Reform of the Market for Medicinal Products.
In a small study that included 25 patients with hereditary hemorrhagic telangiectasia (a genetic disorder that leads to abnormalities of blood vessels) and severe liver involvement with this disease, patients who received the drug bevacizumab had improved cardiac output and a reduction in the duration and number of episodes of nose bleeds, a potentially life-threatening complication for patients with this disorder, according to a study in the March 7 issue of JAMA.
› Verified 3 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
Patients included in arterial venous fistula and catheter summaries | 40 |
Patient months included in arterial venous fistula and catheter summaries | 359 |
Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 64 |
Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 9 |
News Archive
The first phase of a landmark study of complications of tuberculosis - the first ever carried out in Africa - has been completed by researchers at Wythenshawe Hospital and the University of Manchester working with colleagues in Uganda.
Several organization led by the WHO have contributed $5 billion for a campaign aimed at distributing 700 million bednets to prevent malaria in sub-Saharan Africa by 2015, the East African reports.
Vismodegib (trade name: Erivedge) has already been approved since 2013 for the treatment of patients with locally advanced basal cell carcinoma (BCC) or symptomatic metastatic BCC and has already undergone an early benefit assessment according to the Act on the Reform of the Market for Medicinal Products.
In a small study that included 25 patients with hereditary hemorrhagic telangiectasia (a genetic disorder that leads to abnormalities of blood vessels) and severe liver involvement with this disease, patients who received the drug bevacizumab had improved cardiac output and a reduction in the duration and number of episodes of nose bleeds, a potentially life-threatening complication for patients with this disorder, according to a study in the March 7 issue of JAMA.
› Verified 3 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
Patients in facility's Hospitalization Summary | 48 |
Hospitalization Rate in facility | 145.7 (As Expected) |
Hospitalization Rate: Upper Confidence Limit | 273.8 |
Hospitalization Rate: Lower Confidence Limit | 81.1 |
News Archive
The first phase of a landmark study of complications of tuberculosis - the first ever carried out in Africa - has been completed by researchers at Wythenshawe Hospital and the University of Manchester working with colleagues in Uganda.
Several organization led by the WHO have contributed $5 billion for a campaign aimed at distributing 700 million bednets to prevent malaria in sub-Saharan Africa by 2015, the East African reports.
Vismodegib (trade name: Erivedge) has already been approved since 2013 for the treatment of patients with locally advanced basal cell carcinoma (BCC) or symptomatic metastatic BCC and has already undergone an early benefit assessment according to the Act on the Reform of the Market for Medicinal Products.
In a small study that included 25 patients with hereditary hemorrhagic telangiectasia (a genetic disorder that leads to abnormalities of blood vessels) and severe liver involvement with this disease, patients who received the drug bevacizumab had improved cardiac output and a reduction in the duration and number of episodes of nose bleeds, a potentially life-threatening complication for patients with this disorder, according to a study in the March 7 issue of JAMA.
› Verified 3 days ago
The rate of readmission show you whether patients who were being treated regularly at Dialysis Clinic, Inc were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
Readmission Rate in facility | 28.5 (As Expected) |
Readmission Rate: Upper Confidence Limit | 43 |
Readmission Rate: Lower Confidence Limit | 16.8 |
News Archive
The first phase of a landmark study of complications of tuberculosis - the first ever carried out in Africa - has been completed by researchers at Wythenshawe Hospital and the University of Manchester working with colleagues in Uganda.
Several organization led by the WHO have contributed $5 billion for a campaign aimed at distributing 700 million bednets to prevent malaria in sub-Saharan Africa by 2015, the East African reports.
Vismodegib (trade name: Erivedge) has already been approved since 2013 for the treatment of patients with locally advanced basal cell carcinoma (BCC) or symptomatic metastatic BCC and has already undergone an early benefit assessment according to the Act on the Reform of the Market for Medicinal Products.
In a small study that included 25 patients with hereditary hemorrhagic telangiectasia (a genetic disorder that leads to abnormalities of blood vessels) and severe liver involvement with this disease, patients who received the drug bevacizumab had improved cardiac output and a reduction in the duration and number of episodes of nose bleeds, a potentially life-threatening complication for patients with this disorder, according to a study in the March 7 issue of JAMA.
› Verified 3 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Dialysis Clinic, Inc get infections in their blood each year compared to the number of infections expected for the center based on the national average.
Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
Infection Rate in facility | 1.59 (As Expected) |
SIR: Upper Confidence Limit | 3.53 |
SIR: Lower Confidence Limit | .58 |
News Archive
The first phase of a landmark study of complications of tuberculosis - the first ever carried out in Africa - has been completed by researchers at Wythenshawe Hospital and the University of Manchester working with colleagues in Uganda.
Several organization led by the WHO have contributed $5 billion for a campaign aimed at distributing 700 million bednets to prevent malaria in sub-Saharan Africa by 2015, the East African reports.
Vismodegib (trade name: Erivedge) has already been approved since 2013 for the treatment of patients with locally advanced basal cell carcinoma (BCC) or symptomatic metastatic BCC and has already undergone an early benefit assessment according to the Act on the Reform of the Market for Medicinal Products.
In a small study that included 25 patients with hereditary hemorrhagic telangiectasia (a genetic disorder that leads to abnormalities of blood vessels) and severe liver involvement with this disease, patients who received the drug bevacizumab had improved cardiac output and a reduction in the duration and number of episodes of nose bleeds, a potentially life-threatening complication for patients with this disorder, according to a study in the March 7 issue of JAMA.
› Verified 3 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Dialysis Clinic, Inc's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
Patients in facility's Transfusion Summary | 38 |
Transfusion Rate in facility | 56 (As Expected) |
Transfusion Rate: Upper Confidence Limit | 149.2 |
Transfusion Rate: Lower Confidence Limit | 23.7 |
News Archive
The first phase of a landmark study of complications of tuberculosis - the first ever carried out in Africa - has been completed by researchers at Wythenshawe Hospital and the University of Manchester working with colleagues in Uganda.
Several organization led by the WHO have contributed $5 billion for a campaign aimed at distributing 700 million bednets to prevent malaria in sub-Saharan Africa by 2015, the East African reports.
Vismodegib (trade name: Erivedge) has already been approved since 2013 for the treatment of patients with locally advanced basal cell carcinoma (BCC) or symptomatic metastatic BCC and has already undergone an early benefit assessment according to the Act on the Reform of the Market for Medicinal Products.
In a small study that included 25 patients with hereditary hemorrhagic telangiectasia (a genetic disorder that leads to abnormalities of blood vessels) and severe liver involvement with this disease, patients who received the drug bevacizumab had improved cardiac output and a reduction in the duration and number of episodes of nose bleeds, a potentially life-threatening complication for patients with this disorder, according to a study in the March 7 issue of JAMA.
› Verified 3 days ago
The rate of mortality show you whether patients who were being treated regularly at Dialysis Clinic, Inc lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
Patients in facility's Survival Summary | 209 |
Mortality Rate in facility | 16.7 (As Expected) |
Mortality Rate: Upper Confidence Limit | 23.4 |
Mortality Rate: Lower Confidence Limit | 11.6 |
News Archive
The first phase of a landmark study of complications of tuberculosis - the first ever carried out in Africa - has been completed by researchers at Wythenshawe Hospital and the University of Manchester working with colleagues in Uganda.
Several organization led by the WHO have contributed $5 billion for a campaign aimed at distributing 700 million bednets to prevent malaria in sub-Saharan Africa by 2015, the East African reports.
Vismodegib (trade name: Erivedge) has already been approved since 2013 for the treatment of patients with locally advanced basal cell carcinoma (BCC) or symptomatic metastatic BCC and has already undergone an early benefit assessment according to the Act on the Reform of the Market for Medicinal Products.
In a small study that included 25 patients with hereditary hemorrhagic telangiectasia (a genetic disorder that leads to abnormalities of blood vessels) and severe liver involvement with this disease, patients who received the drug bevacizumab had improved cardiac output and a reduction in the duration and number of episodes of nose bleeds, a potentially life-threatening complication for patients with this disorder, according to a study in the March 7 issue of JAMA.
› Verified 3 days ago
News Archive
The first phase of a landmark study of complications of tuberculosis - the first ever carried out in Africa - has been completed by researchers at Wythenshawe Hospital and the University of Manchester working with colleagues in Uganda.
Several organization led by the WHO have contributed $5 billion for a campaign aimed at distributing 700 million bednets to prevent malaria in sub-Saharan Africa by 2015, the East African reports.
Vismodegib (trade name: Erivedge) has already been approved since 2013 for the treatment of patients with locally advanced basal cell carcinoma (BCC) or symptomatic metastatic BCC and has already undergone an early benefit assessment according to the Act on the Reform of the Market for Medicinal Products.
In a small study that included 25 patients with hereditary hemorrhagic telangiectasia (a genetic disorder that leads to abnormalities of blood vessels) and severe liver involvement with this disease, patients who received the drug bevacizumab had improved cardiac output and a reduction in the duration and number of episodes of nose bleeds, a potentially life-threatening complication for patients with this disorder, according to a study in the March 7 issue of JAMA.
› Verified 3 days ago